

ORIGINAL ARTICLE

# Evaluation of adrenocortical function in 3-7 aged asthmatic children treated with moderate doses of fluticasone propionate: reliability of dehydroepiandrosterone sulphate (dhea-s) as a screening test

U.M. Sahiner<sup>a,\*</sup>, S. Cetinkaya<sup>b</sup>, S. Ozmen<sup>a</sup>, Z. Arslan<sup>a</sup>

<sup>a</sup> Dr Sami Ulus Children's Hospital, Department of Pediatric Allergy 06080 Ankara, Turkey <sup>b</sup> Dr Sami Ulus Children's Hospital, Department of Pediatric Endocrinology 06080 Ankara, Turkey

Received 20 March 2010; accepted 24 June 2010 Available online 22 January 2011

KEYWORDS	Abstract
KEYWORDS Asthma; children; dehydroepiandrosterone sulphate; adrenal axis supression; fluticasone propionate	<ul> <li>Background: Inhaled corticosteroids (ICS) are the first-line therapy in the treatment of persistent asthma. At medium to high doses and prolonged usage, ICS can supresss the hypothalamic-pituitary-adrenal axis. Dehydroepiandrosterone sulphate (DHEA-S) is a corticotropin-dependent adrenal androgen precursor that is supressible in patients treated with ICS. <i>Objectives:</i> To evaluate the adrenal axis in asthmatic children treated with moderate doses of fluticasone propionate and to evaluate the DHEA-S as a possible marker for adrenal axis in preadrenarchal children.</li> <li><i>Methods:</i> Twenty-eight children with persistent asthma with a mean age of 4.4 years (median 4.2; range 2.5-7.1) on long term treatment (mean 6.16; median 6; range 4.5-9 months) with moderate doses (mean 250; median 253; range 158-347 (g/m<sup>2</sup>/day) of inhaled fluticasone propionate were evaluated with low-dose ACTH stimulation test to assess adrenal function, and DHEA-S levels were compared with the results.</li> <li><i>Results:</i> One out of 28 patients (3.57%) demonstrated an abnormal cortisol response to low-dose ACTH test. There was no correlation between DHEA-S and peak cortisol, morning cortisol and fasting blood glucose levels. However, mean inhaled corticosteroid dosages were inversely correlated with the DHEA-S.</li> <li><i>Conclusions:</i> In most of the children with persistent asthma, mild to moderate fluticazone propionate doses supress the hypothalamic-pituitary-adrenal axis rarely. Chronic moderate doses of ICS may suppress adrenal androgen levels without supression of cortisol production. DHEA-S levels may be used as a practical method to follow adrenal functions and may be an earlier indicator of adrenal dysfunction in children.</li> </ul>
	© 2010 SEICAP. Published by Elsevier España, S.L. All rights reserved.

\* Corresponding author.

E-mail address: umsahner@yahoo.com (U.M. Sahiner).

0301-0546/\$ - see front matter @ 2010 SEICAP. Published by Elsevier España, S.L. All rights reserved. doi:10.1016/j.aller.2010.06.005

#### Introduction

Inhaled corticosteroids (ICS) are the first-line treatment in the management of persistent asthma.<sup>1</sup> Recently there have been reports of symptomatic adrenal insufficiency in children on chronic ICS treatment.<sup>2–4</sup> Most of these children were treated with high doses of inhaled fluticasone. For most patients aged <12 years, the recommended dose of fluticasone propionate (FP) is classified as low (88-176  $\mu$ g/day); medium (176-440  $\mu$ g/day); or high (> 440  $\mu$ g/day).<sup>1</sup> Fluticasone has the highest receptor binding affinity of any of the commercially available ICS.<sup>5</sup> Use of FP has been reported to produce dose-related adrenal suppression greater than that of other commercially available ICS.<sup>6–8</sup> Studies using low or medium doses of FP in adults with mild to moderate asthma have conflicting results.<sup>9–12</sup> Children may be even more susceptible to adrenal supression than adults. The number of studies concerning the effects of FP on adrenal axis at low to medium doses in children is limited and results are also conflicting.<sup>13–16</sup>

For the evaluation of the hypothalamic-pituitary-adrenal (HPA) axis, insulin induced hypoglycaemia and metyrapone are considered the most sensitive tests but they are associated with unpleasant symptoms and significant potential complications.<sup>17</sup> Recently, low dose cosyntropin has been found to be a sensitive test for determining adrenal supression.<sup>18–20</sup> However, it is an invasive and time-consuming test and not reliable for screening purposes.

Dehydroepiandrosterone sulphate (DHEA-S) is an adrenal androgen precursor secreted by the zona reticularis, under the dominant regulation of corticotropin. Serum levels of DHEA-S are affected by several factors, the most important of which are age, gender, chronic illness and the prior use of glucocorticoids. DHEA-S has a long half-life (10-12 hours) and concentrations do not fluctuate throughout the day.<sup>21</sup> There are some reports indicating that the adrenal androgen secretion is sensitive and suppressible with the exogenous glucocorticoids.<sup>22–24</sup> However, data on the use of DHEA-S in the assessment of adrenal function, especially in preadrenarchal children, are limited.

In the present study, we evaluated the effect of moderate doses of FP on HPA axis in preadrenarchal children and compared the results with DHEA-S levels. Our aim was to document the effects of FP at moderate doses in HPA and determine whether there was a correlation between DHEA-S levels and HPA functions in preadrenarchal children.

# Patients and methods

Twenty-eight children with persistent asthma and using moderate doses of fluticasone propionate between doses of 158-347  $\mu$ g/m<sup>2</sup>/day and for at least 4 months were enrolled in the study. Patients were all at preadrenarchal ages and this was confirmed by a detailed physical examination. None of the children were exposed to systemic corticosteroids more than two courses (each of which at most 5 days and 1 mg/kg/day) within the last 6 months. Any patient with exposure of systemic or topical corticosteroids one month before the adrenal function testing or with a history of chronic illnesses other than asthma were excluded from the study. This study was approved by the ethics committee of

Dr Sami Ulus Children's Hospital numbered 0016/2007 and informed consent was obtained by the parents of each child who participated in the sudy.

Detailed clinical histories were obtained from the previous medical records, including length of time of exposure and dose of fluticasone propionate. Children were admitted to the Dr Sami Ulus Children's Hospital paediatric allergy and paediatric endocrinology out-patient units with a history of 12 hours fasting and they all stopped the ICS usage 24 hours prior to admission. First an experienced paediatric endocrinologist made a detailed physical examination and patients with the signs of adrenarche were excluded form the study. Half an hour after inserting an intravenous tube the baseline laboratory measures including morning cortisol (between 9:00 and 9:30 a.m.), fasting blood glucose and DHEA-S levels were taken. Then low-dose ACTH ( $0.5 \,\mu g/m^2$ up to a maximum of  $1 \mu g$ ) was administered intravenously, and the cortisol levels were measured at the 10<sup>th</sup>, 20<sup>th</sup>, 30<sup>th</sup>, and 40<sup>th</sup> minutes. A cortisol level of 19.8 µg/dl or greater was considered as passing the test.<sup>25</sup>

DHEA-S levels were measued by means of chemiluminescence immunoassays using a commercial kit (DHEA-S radioimmunoassay; Diagnostic Systems Laboratories, Inc., Webster, TX, USA); and cortisol levels were measured by means of enzyme immunoassays using the ST AIA PACK CORT system (TOSOH Bioscience, San Francisco, CA, USA).

The data were analysed by using SPSS version 8.0 (SPSS Inc.Chicago, IL, USA). Pearson's correlation coefficient was used to analyse the relationship between DHEA-S and inhaled costicosteroid, morning cortisol, peak cortisol, and fasting blood glucose levels. The level of statistical significance was at 5%.

# Results

The average age of the patients was 4.4 (median 4.2, range 2.5-7.1) and the male-female ratio was 17/11. Demographic data and the other characteristics of patients are shown in Table 1.

One out of 28 asthmatic children (3.57%) demonstrated biochemical adrenal suppression, that is he had a peak serum cortisol response to low-dose ACTH test <19.8 µg/dl. No patient presented symptoms suggestive of adrenal insufficiency. When Pearson's correlation coefficient test was performed no significant correlations were found between DHEA-S and fasting blood glucose levels (r = 0.157; p = 0.424); DHEA-S and morning cortisol levels (r=0.279; p=0.150) (Figure 1) and between DHEA-S and peak cortisol levels (r = -0.006; p = 0.976). There was no correlation between the mean inhaled corticosteroid dose and morning cortisol or peak cortisol levels either (r = -0.140; p = 0.478 and r = -0.61; p = 0.759 respectively). Mean inhaled corticosteroid dosage of the patients was  $250 \,\mu g/m^2/day$ (median 253, range 158 to 347) and there was an inverse correlation between the mean ICS dosages and DHEA-S levels of the patients (r = -0.440; p = 0.019) (Figure 2).

#### Discussion

Inhaled corticosteroids (ICS) are the first-line treatment in the management of persistent asthma.<sup>1</sup> There have been

Characteristic	Mean $\pm$ Standard deviation	Median, Range
Patients (n), Male/Female	28, 17/11	
Age, years	4.4±1.3	(4.1; 2.5 to 7.1)
ICS <sup>a</sup> dosage $\mu$ g/m <sup>2/</sup> day	$250\pm44,8$	(253; 158 to 347)
Duration of treatment months	6.16±1.1	(6; 4.5 to 9)
FBG <sup>b</sup> mg/dl	84.1±9.7	(85.5; 59 to 104)
Morning cortisol µg/dl	$10.7 \pm 3.6$	(10.6; 5.1 to 18.2)
Peak cortisol µg/dl	$28.4 \pm 7.9$	(26.1; 18.8 to 59.4)
DHEA-S µg/dl	15.4±9.3	(12.2; 3.3 to 42.4)

 Table 1
 Demographic and other characteristics of the patients

<sup>a</sup>ICS: Inhaled corticosteroids, <sup>b</sup>FBG: Fasting blood glucose.

reports of symptomatic adrenal insufficiency in children who were treated with high doses of inhaled fluticasone.<sup>2-4</sup> In adolescent and adult asthmatics most of the therapeutic benefit of FP is achieved at doses of 100-250  $\mu$ g/day and the use of FP in doses up to 500  $\mu$ g/day rarely causes adrenal supression.<sup>26</sup>

In children, comparable dose response relation for FP has not been formally established for either efficacy or adrenal supression. There have been reports of symptomatic adrenal insufficiency<sup>2,27,28</sup> including acute adrenal crisis<sup>3,4,29</sup> attributed to FP therapy at doses >500  $\mu$ g/day in asthmatic children. The presented data show that fluticasone propionate at medium doses <400  $\mu$ g/m<sup>2</sup>/day (or nearly 200-250  $\mu$ g/day at studied age group) does not cause adrenal supression in children. Only one out of 28 children (3.57%) showed biochemical supression of HPA. No symptomatic adrenal insufficiency observed.

Eid et al. made an observational study of 62 children for 8 months and abnormal morning cortisol levels were found in

17% (1/6) of children receiving low-dose (176  $\mu$ g/day), and in 43% (12/28) of children rceiving high-dose (>880  $\mu$ g/day) FP.<sup>30</sup> In the study of Peden et al., fluticasone doses up to 200  $\mu$ g/day did not change the 24-hour urinary cortisol levels.<sup>13</sup> In another study Verona et al. showed that FP at 400  $\mu$ g/day caused adrenal supression in a small but clinically significant proportion of children, compared with the 200  $\mu$ g/day dose.<sup>31</sup> A similar result was found by Kannisto et al. in which 20% of the asthmatic children had an abnormal response at 500  $\mu$ g/day.<sup>19</sup> Taken together, these results suggest that fluticasone propionate is unlikely to cause adrenal supression at 200  $\mu$ g/day and adrenal supression occuring in some children at 400 to 500  $\mu$ g/day.<sup>13,15,19,30</sup>

Since ICS can cause adrenal supression at high doses in asthmatic children, assessment of the adrenal functions during the treatment period is an important issue.<sup>2–4</sup> For the evaluation of HPA axis, insulin-induced hypoglycaemia and metyrapone are considered the most sensitive tests but they are associated with significant potential





Figure 1 No correlation was found between dehydroepiandrosterone sulphate and morning cortisol levels (Pearson's correlation coefficient r = 0.279; p = 0.150).



**Figure 2** There was an inverse correlation between dehydroepiandrosterone sulphate levels and mean inhaled corticosteroid dosages used by patients (Pearson's correlation coefficient (r = -0.440; p = 0.019).

complications.<sup>17</sup> Low-dose cosyntropin has been found to be a sensitive test for determining adrenal supression.<sup>18–20</sup> However, it is an invasive test requiring intravenous cannula and repeated blood samples and not reliable for screening purposes.

Dehydroepiandrosterone sulhpate (DHEA-S) is an adrenal androgen under the dominant regulation of corticotropin and has a longer half-life (10-12 hours) than cortisol (<2 hours). Thus, diurnal changes in serum DHEA-S concentrations are much lower than cortisol.<sup>21</sup> Levels of DHEA-S have been shown to be decreased in asthmatic patients exposed to high ICS doses.<sup>22–24</sup> In the present study, serum DHEA-S levels correlated inversely with the mean inhaled coticosteroid levels and a dose-dependent decrease was found in preadrenarchal asthmatic children. The same correlaton was not found with the peak plasma cortisol levels and low-dose ACTH stimulation test revealed only one patient with the biochemical evidence of adrenal supression. These findings support the studies of Cutler et al. and Rittmaster et al. who found that adrenal androgen secretion is more sensitive than cortisol production to the supressive effect of glucocorticoid therapy.<sup>31,32</sup> Kreitzer et al. did not find any decrease in DHEA-S levels in preadrenarchal children after a short one-week course of prednisone, even though the decrease in postadrenarchal children was significant.<sup>33</sup> In a preadrenarchal child there may also be alternative ACTH independent regulatory pathways of DHEA-S synthesis. However if the dosage or the duration of the corticosteroids increase as in the present study, DHEA-S levels decrease with the supressive effects of ICS.

Hypoglycaemia was not found in any of the patients and there was not a correlation between DHEA-S levels and fasting blood glucose levels as expected. In adrenal axis supression, hypoglcaemia is a result of loss of gluconeogenic effect of cortisol and we found cortisol function loss in only one out of twenty-eight patients with low-dose ACTH test. That is why we could not find hypoglycaemia in the study group.

In the present study, morning cortisol levels were not correlated with the DHEA-S levels. A morning cortisol level may be practical to assess the adrenal functions. However, it has been shown to be an insensitive measure of adrenal function in different studies.<sup>24,34</sup>

In conclusion, fluticasone propionate is unlikely to cause adrenal supression at moderate doses (<400  $\mu$ g/m<sup>2</sup>/day), and conventional doses of inhaled corticosteroids in preadrenarchal children may suppress DHEA-S production. The presence of low DHEA-S levels may be used as a screening test to identify the child who needs further evaluation of adrenal supression.

# Conflict of interest

The authors have no conflict of interest to declare.

#### References

- 1. National Asthma Education and Practice Program. Guidelines for the diagnosis and management of asthma: update on selected topics-2002. J Allegy Clin Immunol. 2002; 110 Suppl 5: S141-S219.
- Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D. Growth and adrenal supression in asthmatic children treated with high dose fluticasone propionate. Lancet. 1996;348:27–9.
- Patel L, Wales JK, Kibirige MS, Massarano AA, CourielJM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child. 2001;85:330–4.

- 4. Drake AJ, Howells RJ, Shield JP, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ. 2002;324:1081–2.
- Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91 Suppl A:22-8.
- Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arc Intern Med. 1999;159:941–55.
- Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. For the Asthma Clinical Research Network of the National Heart. Lung and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410–8.
- Brus R. Effects of high dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Arch Intern Med. 1999;159:1903–8.
- Jarvis B, Faulds D. Inhaled fluticasone propionate: A review of its therapeutc efficacy at dosages < or =500 mikrog/day in adults and adolescents with mild to moderate asthma. Drugs. 1999;57:769–803.
- Chervinsky P, Van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, et al., For the Fluticasone Propionate Asthma Study Group. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994;94:676–83.
- 11. Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999;116:931-4.
- Nelson HS, Stricker W, Casale TB, Raff H, Fourre JA, Aron DC, et al. A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids. J Clin Pharmacol. 2002;42:319–26.
- Peden D, Berger W, Noonan M, Thomas MR, Hendrics VL, Hamedani AG, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large paediatric population with persistent asthma. J Allergy Clin Immunol. 1998;102:32–8.
- Hoekstra MO, Grol MH, Bouman K, Stijnen T, Köeter GH, Kauffman HF, et al. Fluticasone propionate in children with moderate asthma. Am J Respir Crit Care Med. 1996;154:1039–44.
- Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Medley H, et al. Fluticasone propionate in asthma: a long term dose comparison study. Arch Dis Child. 2003;88:503–9.
- Price J, Russell G, Hindmarsh P, Weller P, Heaf DP, Wiliams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol. 1997;24:178-86.
- Zöllner EW. Hypothalamic-pituitary-adrenal axis supression in asthmatic children on inhaled corticosteroids: Part 1. Which test should be used? Pediatr Allergy Immunol. 2007;18:401–9.
- Fitzgerald D, Van Asperen P, Melis C, Honner M, Smith L, Ambler G. Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax. 1998;53:656–61.
- 19. Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal supression, evaluated by a low dose adrenocorticotropin test, and

growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2000;85:652–7.

- Broide J, Soferman R, Kivity S, Golander A, Dickstein G, Spirer Z, et al. Low dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995;80:1243–6.
- Parker LN. Control of adrenal androgen secretion. Endocrinol Metab Clin North Am. 1991;20:401–21.
- 22. Kannisto S, Laatikainen A, Taivainen A, Savolainen K, Tukiainen H, Voutilainen R. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients. Eur J Endocrinol. 2004;150:687–90.
- Kannisto S, Korppi M, Remes K, Voutilainen R. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical supression in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2001;86:4908–12.
- Dorsey MJ, Cohen LE, Phipatanakul W, Denufrio D, Schneider LC. Assessment of adrenal supression in children with asthma treated with inhaled corticosteroids: use of dehydroepiandrosterone sulfate as a screening test. Ann Allergy Asthma Immunol. 2006;97:182–6.
- 25. Gonc EN, Kandemir N, Kinik ST. Significance of low-dose and standard-dose ACTH tests compared to overnight metyrapone test in the diagnosis of adrenal insufficiency in childhood. Horm Res. 2003;60:191–7.
- Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone proionate in adolescents and adults with asthma: meta analysis. BMJ. 2001;323:253–6.
- Taylor AV, Laoprasert N, Zimmerman D, Sachs MI. Adrenal supression secondary to inhaled fluticasone propionate. Ann Allergy Asthma Immunol. 1999;83:68–70.
- Wong J, Zacharin M, Hocking N, Robinson PJ. Growth and adrenal supression in asthmatic children on moderate to high doses of fluticasone propionate. J Paediatr Child Health. 2002;38:59–62.
- Todd GRG, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002;87:457–61.
- Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics. 2002;109:217–21.
- Cutler Jr GB, Davis SE, Johnsonbaugh RE, Loriaux DL. Dissociation of cortisol and adrenal androgen secretion in patients with secondary adrenal insufficiency. J Clin Endocrinol Metab. 1979;49:604–9.
- Rittmaster RS, Loriaux DL, Cutler Jr GB. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. J Clin Endocrinol Metab. 1985;61:462–6.
- Kreitzer PM, Blethen SL, Festa RS, Chasalow FI. Deyhdroepiandrosterone sulfate levels are not supressible by glucocorticoids before adrenarche. J Clin Endocrinol Metab. 1989;69:1309–11.
- Ferguson AC, Spier S, Manjra A, Versteegh FGA, Mark S, Zhang P. Efficacy and safety of high dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422–7.